

Memorial Sloan Kettering Cancer Center

New FDA Approvals: Update

Steven M. Horwitz M.D. Lymphoma Service Memorial Sloan Kettering Cancer Center

Stage Based Approach

- Early Stage = skin only, patches and plaques
- Skin directed therapy only
- Skin directed therapy + other
- "Milder" systemic therapies
- Advanced stage IIB-IV (tumors or disease outside the skin)
- Often include systemic therapy (outside skin-yes)
- Slower growing, less symptomatic, long term approach
- "Milder" medications, little cumulative toxicity
 - retinoids, interferon, hdac inhibitors, immunotherapy,



National

Comprehensive

NCCN Cancer Network*

NCCN Guidelines Version 3.2018 Mycosis Fungoides/Sezary Syndrome

NCCN Guidelines Index Table of Contents Discussion

SKIN-DIRECTED THERAPIES

For limited/localized skin involvement (Skin-Limited/Local)

- Topical corticosteroids^b
- Topical chemotherapy (mechlorethamine [nitrogen mustard])
- Local radiation (8-12 Gy; 24-30 Gy for unilesional presentation)^C
- Topical retinoids (bexarótene, tazarotene)
- Phototherapy (UVB, NB-UVB for patch/ thin plaques; PUVA for thicker plaques)^d
- Topical imiquimod

For generalized skin involvement (Skin-Generalized)

- Topical corticosteroids^b
- Topical chemotherapy (mechlorethamine [nitrogen mustard])
- Phototherapy (UVB, NB-UVB, for patch/ thin plaques; PUVA for thicker plaques)^d
- Total skin electron beam therapy (TSEBT) (12–36 Gy)^{C,0,1}

SUGGESTED TREATMENT REGIMENS^a

SYSTEMIC THERAPIES

Category A (SYST-CAT A)

- Retinoids (bexarotene, all-trans retinoic acid, isotretinoin [13-cis-retinoic acid], acitretin)¹
- Interferons (IFN-alpha, IFN-gamma)
- HDAC-inhibitors (vorinostat, romidepsin)^T
- Extracorporeal photopheresis^g
- Methotrexate (≤100 mg q week)
- Brentuximab vedotin^h

Category B (SYST-CAT B)

- Preferred therapies (alphabetical order)
- Brentuximab vedotin^h
- Gemcitabine
- Liposomal doxorubicin
- Low-dose pralatrexate
- Other therapies
- Chlorambucil
- Pentostatin
- Etoposide
- Cyclophosphamide
- Temozolomide
- Methotrexate (>100 mg q week)
- Pembrolizumab^I (category 2B)
- Bortezomib (category 3)

SYSTEMIC THERAPIES (continued)

Category C (SYST-CAT C) (alphabetical order)

- Bortezomib (category 3)
- Brentuximab vedotin¹
- Gemcitabine
- Liposomal doxorubicin
- Low- or standard-dose pralatrexate
- Romidepsin
- See regimens listed on <u>TCEL-B 2 of 5</u> (PTCL-NOS)^k

COMBINATION THERAPIES

Skin-directed + Systemic

- Phototherapy + retinoid
- Phototherapy + IFN
- Phototherapy + photopheresis^g
- Total skin electron beam^{*} + photopheresis⁹

Systemic + Systemic

- Retinoid + IFN
- Photopheresis^g + retinoid
- Photopheresis⁹+ IFN
- Photopheresis^g + retinoid + IFN



Brentuximab Vedotin Demonstrates Significantly Superior Clinical Outcomes in Patients With CD30-Expressing Cutaneous T-Cell Lymphoma Versus Physician's Choice (Methotrexate or Bexarotene): the Phase 3 ALCANZA study

ALCANZA investigators

Australia: Judith Trotman, David Joske, H. Miles Prince, Kerry Taylor, Ian D. Lewis

Austria: Constanze Jonak, Franz Trautinger

Belgium: Oliver Bechter (Pascal Wolter), Dominique Bron

Brazil: Vladmir Claudio C. de Lima, Jose Antonio Sanches Junior


Canada: Richard Klasa

France: Martine Bagot, Marie Beylot-Barry, Stephane Dalle, Michel D'Incan, Brigitte Dreno, Florent Grange
Germany: Jan Nicolay, Rudolf Stadler, Michael Weichenthal, Marion Wobser, Chalid Assaf, Carmen Loquai
Italy: Pietro Quaglino, Michele Spina, Pier Luigi Zinzani, Alberto Bosi, Pier Paolo Fattori
Poland: Aleksandra Grzanka, Jan Walewski
Spain: Andres Lopez-Hernandez, Pablo L. Ortiz-Romero, Jose Juan Rifon Roca, Silvana Novelli Canales
Switzerland: Reinhard Dummer

United Kingdom: Timothy Illidge, Rod Johnson, Sean Whittaker (Stephen Morris), Pam McKay, Julia Scarisbrick


United States: Madeleine Duvic, Tatyana Feldman, Oleg Akilov (Larisa Geskin), Steve Horwitz, Youn H. Kim, Barbara Pro (Timothy Kuzel), Adam Lerner, Herbert Eradat, Lubomir Sokol, David C. Fisher, Sarah Hughey

Antibodies






Antibody Drug Conjugates (ADCs)





Antibody Drug conjugates




Background and rationale

- Brentuximab vedotin, a CD₃o targeting antibody-drugconjugate
- 2 Phase 2 studies showed promising activity
- This was the first reported phase 3 trial of a new systemic agent tested against standard therapy in CTCL



ALCANZA: a randomized, open-label, phase 3 trial of brentuximab vedotin vs physician's choice (methotrexate or bexarotene) in patients with CD30+ CTCL




Patient baseline characteristics: ITT population, N=128

	Brentuximab vedotin (n=64)	Methotrexate or bexarotene (n=64)
Median age, years (range)	62 (22–83)	59 (22–83)
Gender, Male n (%)	33 (52)	37 (58)
Early (IA-IIA)	15 (31)	18 (37)
Advanced (IIB-IVB**)	32 (67)	30 (61)
Prior therapies, median (range)	4.0 (0–13)	3.5 (1–15)
Prior systemic therapies, median (range)	2.0 (0–11)	2.0 (1–8)



Maximum percent change in skin mSWAT score




* Indicates % change in mSWAT is o

Primary and key secondary endpoint analyses (ITT population)

Endpoint	Brentuxim ab vedotin N=64	Physician' s Choice N=64	Statistical Significance
Primary endpoint			
ORR4, n (%)	36 (56.3)	8 (12.5)	p<0.0001
Key secondary endpoints			
CR, n (%)	10 (15.6)	1 (1.6)	p=0.0046 ^{adj}
Mean maximum reduction in Skindex- 29 symptom domain, points	-27.96	-8.62	p<0.0001 ^{adj}



Commonly reported (≥15% of patients) treatmentemergent AEs



Percentage incidence


*No Gr 4 peripheral neuropathy was reported in the brentuximab vedotin (26% Gr 1, 32% Gr 2, 9% Gr 3) or physician's choice arms (2% Gr 1, 5% Gr 2). At last follow-up (median 22.9 months), 36/44 (82%) patients in the brentuximab vedotin arm had improvement or resolution of peripheral neuropathy.

**Elevated triglycerides, were reported in 2% of patients receiving brentuximab vedotin versus 30% of patients receiving bexarotene (14% Gr 3, 8% Gr 3

Length of drug exposure: median 12 cycles (36 weeks) of BV vs. 17 weeks of bexarotene or 9 weeks of methotrexate

Memorial Sloan Kettering Cancer Center

ALCANZA: Results by CD₃o expression in MF patients



Time (months)



Summary and conclusions

• First report of a randomized phase 3 trial in CTCL with convincing demonstration of improved efficacy of a new systemic agent over standard-of-care options

• Brentuximab vedotin showed superior efficacy outcomes over physician's choice of either bexarotene or methotrexate in MF and pcALCL (CD30 expressing CTCL).





Memorial Sloan Kettering Cancer Center

Anti-CCR4 Monoclonal Antibody, Mogamulizumab, Demonstrates Significant Improvement in PFS Compared to Vorinostat in Patients with Previously Treated Cutaneous T-Cell Lymphoma: Results from the Phase 3 MAVORIC Study

MAVORIC Investigators


- **US:** Alison J. Moskowitz, Erin Boh, Amy Musiek, Mary Jo Lechowicz, Francine Foss, Larisa Geskin, S. Onder Alpdogan, Ronald Peter Rapini, John P. Greer, Timothy Fenske, Ellen Kim, Youn Kim, Basem William, Herbert Eradat, Barbara Pro, Lubomir Sokol, Andrei Shustov, Oleg Akilov, Theresa Pacheco, Craig Elmets, Brian Poligone, Michael D. Tharp, Ryan A. Wilcox, Frederick Lansigan, Neil Korman, Lawrence A. Mark, Ahmad Sami Halwani, Adam Lerner, Zanetta Lamar, Sunil Abhyankar, Christiane Querfeld, David C. Fisher, Javier Munoz, Craig Yoshitsugu Okada (Independent Reviewer), Jessica Taft Leonard (Independent Reviewer)
- Australia: Bryone Jean Kuss, Amit Khot, Pratyush Kumar Giri, Jillian Wells
- UK: Stephen Lloyd Morris, Richard Cowan, Julia Scarisbrick

- Japan: Noriko Fukuhara, Kensei Tobinai, Kiyohiko Hatake, Shinsuke Iida, Mikio Otsuka, Osamu Ishikawa, Tomomitsu Miyagaki, Hidefumi Wada, Yoshiki Tokura, Koji Habe, Hiroyuki Okamoto, Eiji Kiyohara, Kentaro Yonekura, Hiroshi Koga, Kaoru Nishiwaki, Maiko Tanaka, Toshihisa Hamada, Jiro Uehara, Shigetoshi Sano
- France: Martine Bagot, Marie Beylot Barry, Stéphane Dalle, Brigitte Dreno
- **Germany:** Jan Peter Nicolay, Nina Magnolo
- Italy: Pier Luigi Zinzani, Maria Teresa Fierro
- **Spain:** Dolores Caballero, Pablo L. Ortiz-Romero

Cancer Center

- **Denmark**: Lars Iversen
- Netherlands: Maarten H. Vermeer
- Switzerland: Reinhard Georg Dummer

Antibodies



Anti-CCR₄ Defucosylated Fc region




MAVORIC Study Design

Inclusion:

- Stage IB IVB histologically confirmed MF or SS (B2)
- At least one prior course of systemic therapy

Exclusion:

• Patients with large cell transformation



• 372 patients were randomized at 59 centers across 11 countries



Background


- In a US-based phase 1/2 study in CTCL, mogamulizumab demonstrated a tolerable safety profile and promising efficacy
- These results led to the development of the MAVORIC trial, a randomized phase 3 study of the efficacy and safety of mogamulizumab versus vorinostat in previously treated patients with CTCL

• MAVORIC is the largest randomized study to compare systemic therapies and the first pivotal trial to use PFS as a primary endpoint in CTCL

Patient Baseline Characteristics: ITT population, N=372

	Mogamulizumab (N=186)	Vorinostat (N=186)
Median age (range), years	63 (25, 101)	65 (25, 89)
Male gender (n, %)	109 (59)	107 (58)
Disease type (n, %) MF SS	105 (56) 81 (44)	99 (53) 87 (47)
Current clinical stage (n, %) IB-IIA IIB IIIA-IIIB IVA1 IVA2 IVBª	36 (19) 32 (17) 22 (12) 73 (39) 19 (10) 4 (2)	49 (26) 23 (12) 16 (9) 82 (44) 12 (6) 4 (2)
Median number of prior systemic therapies (range)	3 (1, 18)	3 (0, 14) (筆) Memorial Sloan Cancer Center.

mSWAT Score and Superior Best Global Response



	Mogamulizumab	Vorinostat
ORR ^{a,b} , n/N (%)	52/186 (28)	9/186 (5)
MF ^c	22/105 (21)	7/99 (7)
SS ^b	30/81 (37)	2/87 (2)
DOR, median, months	14	9
MF	13 (n=22)	9 (n=7)
SS	17 (n=30)	7 (n=2)
ORR ^a n (%) mogamulizumab after crossover	41/136 (30)	

^aORR is the percentage of patients with confirmed CR or confirmed PR; ^bP<0.0001; ^cP=0.004.

ORR=overall response rate; TTR=time to response; DOR=duration of response; PRO=patient-reported outcome.




Clinical Activity by Compartment

	Mogamulizumab	
Compartment response rate, n/N (%)		
Skin ORR (CR+PR) CR	78/186 (42) 8 (4)	
Blood ORR (CR+PR) CR	83/124 (67) 54 (44)	
Lymph nodes ORR (CR+PR) CR	21/136 (15) 10 (7)	




Patient-Reported Symptom Reduction as Measured by the Skindex-29 Scale



CDF Curve of Skindex-29 Symptoms Scale Score at Cycle 5



Commonly Reported Treatment-Emergent Adverse Events $(\geq 20\% \text{ of patients})$





Summary and Conclusions

- Mogamulizumab, a novel CCR4-targeting antibody therapy, demonstrated significantly superior efficacy outcomes compared to vorinostat in patients with previously treated CTCL
- Patient-reported outcomes (Skindex-29 and FACT-G) demonstrated significant improvement with mogamulizumab
- The safety profile was consistent with previous reports, and common AEs were manageable
- This study supports mogamulizumab as a valuable new therapeutic option in patients with CTCL




Where would these new drugs fit

- Early Stage probably not right away
 - Maybe if many things had already been tried
- Advanced stage-another option
 - Brentuximab best in tumors, nodes
 - ?CD30 level
 - Sezary? not include in study
 - Neuropathy-intermittent therapy
 - Mogamulizumab-if/when approved
 - Best in Sezary and Blood
 - ? If CCr4 expression needed
 - Transformed to Large Cell not included
 - Seems ok long term-as best we know




Immune Checkpoint Inhibitors

- PD-L1 expressed on malignant cells and/or in the tumor microenvironment
- It can interferes with host antitumor immunity.²



Nivolumab is a fully human IgG4 monoclonal antibody with anti-PD-1 activity.
 ¹Francisco LM et al. J Exp Med 2009;206:3015-29.
 ²Andorsky DJ et al. Clin Cancer Res 2011;17:4232-44


CD47-SIRPα: A Universal Cancer Immune Checkpoint




- CD47 sends a "don't eat me" signal to macrophages and other immune cells
- CD47 is often up-regulated in a wide variety of cancers
- Antibodies that block the CD47:SIRPα interaction potently stimulate macrophage phagocytosis (eat) of cancer cells




Autologous T cells target foreign proteins on diseased cells, but not self proteins




Allogeneic T cells target foreign proteins on diseased cells, but not and self proteins



Generation of CD19-targeted Autologous T cells (CAR) for treatment of B cell Lymphoma



Genetically modified T cells now recognize "non-foreign" tumor cells....



Immunotherapy in CTCL

- T-cell checkpoint inhibitors
 - Approved for other cancers-studies in CTCL (pembrolizumab, nivolumab)
- Anti CD47 Strategies-in clincial trials for CTCL now
- CAR-T cells
 - Approved for B-cell leukemia/lymphoma
 - Ideas for T cell lymphomas including CTCL in idea/preclincial stage
 - "may be a more complicated problem than B-cell lymphoma)
 - Early studies starting in T-ALL
 - Other CARs may also work here-also preclinical



Questions?

